This is a competitive renewal application for the Cancer Center Support Grant of Roswell Park Cancer Institute (RPCI). an NCI-designated Comprehensive Cancer Center, for the grant period 1985 - 2000. Under the leadership of Institute President and CEO, Thomas B. Tomasi, M.D., Ph.D, this grant is entering its 20th year of uninterrupted funding. Over the past two decades, the CCSG has provided indispensable support to the research programs of RPCI. The present CCSG application reflects the significant evolution and progress of RPCIs research programs with the inclusion of 6 mature programs, 2 developing programs and 12 shared resources, seven of which are new or significantly expanded resources carried over from the merger of the Institute Core Grant with the Grace Cancer Drug Center Core Grant. Since the last CCSG renewal, there have been numerous changes in the RPCI research programs including recruitment of new senior faculty, scientific and clinical departments have been reorganized, major capital investments and the commitment of New York State to design and build a new research laboratory, vivarium, nursing tower, ambulatory clinic and diagnostic and treatment facility, all in addition to major renovations to existing research facilities. The CCSG plays a central role in the planning and evaluation, support and administration of Roswell's basic and clinical research programs. With the renewal of this CCSG, combined with the commitment of New York State to support the cancer mission of Roswell Park and its highly dedicated research faculty, Roswell Park will be poised to enter the next century as one of the nations leading cancer centers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-22
Application #
2414072
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1983-12-01
Project End
2000-04-30
Budget Start
1997-06-16
Budget End
1998-04-30
Support Year
22
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Mahoney, Martin C; Erwin, Deborah O; Twarozek, Annamaria Masucci et al. (2018) Leveraging technology to promote smoking cessation in urban and rural primary care medical offices. Prev Med 114:102-106
Cheng, Ting-Yuan David; Darke, Amy K; Redman, Mary W et al. (2018) Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst 110:734-742
Zonneville, Justin; Safina, Alfiya; Truskinovsky, Alexander M et al. (2018) TGF-? signaling promotes tumor vasculature by enhancing the pericyte-endothelium association. BMC Cancer 18:670
Rabi, Thangaiyan; Li, Fengzhi (2018) Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition. Am J Cancer Res 8:2267-2283
Haring, Rodney C; Henry, Whitney Ann; Hudson, Maui et al. (2018) Views on clinical trial recruitment, biospecimen collection, and cancer research: population science from landscapes of the Haudenosaunee (People of the Longhouse). J Cancer Educ 33:44-51
Elahi, Seerat; Egan, Shawn M; Holling, G Aaron et al. (2018) The RNA binding protein Ars2 supports hematopoiesis at multiple levels. Exp Hematol 64:45-58.e9
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Ma, Wen Wee; Xie, Hao; Fetterly, Gerald et al. (2018) A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol :

Showing the most recent 10 out of 1555 publications